This review focuses on recent progress in our understanding of Mycobacterium tuberculosis
survival in macrophages, the interaction of M. tuberculosis with Toll-like receptors (TLRs) …

Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional
tuberculosis treatment, complicated by emerging drug resistances. Host-directed therapies …

Upon infection, mycobacteria, such as Mycobacterium tuberculosis (Mtb) and
nontuberculous mycobacteria (NTM), are recognized by host innate immune cells, triggering …

The continued spread of multidrug-resistant (MDR) tuberculosis and extensively drug-
resistant tuberculosis poses a major threat to global tuberculosis control. Treatment is …

Tuberculosis remains second only to HIV/AIDS as the leading cause of mortality worldwide
due to a single infectious agent. Despite chemotherapy, the global tuberculosis epidemic …

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious
disease with one of the highest morbidity and mortality rates worldwide. Leveraging its …

Host defense strategies against infectious diseases are comprised of both host resistance
and disease tolerance. Resistance is the ability of the host to prevent invasion or to eliminate …

The different manifestations of infection with Mycobacterium tuberculosis reflect the balance
between the bacillus and host defense mechanisms. Traditionally, protective immunity to …

Mycobacterium tuberculosis remains one of the most pernicious of human pathogens.
Current vaccines are ineffective, and drugs, although efficacious, require prolonged …

Mycobacterium tuberculosis (Mtb) is the causative agent of human tuberculosis (TB) which
primarily infects the macrophages. Nearly a quarter of the world's population is infected …